Maartje M. Berends
Almelo, OV, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (BeNeBio study): An International, Pragmatic, Multicentre, Randomised, Controlled, Non-Inferiority Trial.
Journal: The Lancet regional health. Europe
Published: January 29, 2026
Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis.
Journal: Acta dermato-venereologica
Published: December 19, 2024
Lower Drug Survival, Less Satisfaction and More Adverse Events in Females Using Biologics for Psoriasis: Results of the Dutch BioCAPTURE Registry.
Journal: Journal of psoriasis and psoriatic arthritis
Published: December 13, 2024
Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment.
Journal: American journal of clinical dermatology
Published: April 28, 2024
Impairment in work and activities of daily life in patients with psoriasis: results of the prospective BioCAPTURE registry.
Journal: The Journal of dermatological treatment
Published: January 24, 2024
Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort.
Journal: Acta dermato-venereologica
Published: March 31, 2022
Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study.
Journal: Acta dermato-venereologica
Published: November 16, 2020
A neonate with a skin lesion of the scalp
Journal: Nederlands tijdschrift voor geneeskunde
Published: December 11, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026